endocrine/exocrine glands
• increased apoptosis of beta cells at age P14
|
• decreased number of proliferating insulin+ cells at age P1 and P14
• number of proliferating insulin+ cells at embryonic age E18.5
|
• 50% reduction at age P1 and 85% at age P56
• at embryonic age E18.5
|
• proliferating insulin+ cells at age P1 and P14
• at age P35
• proliferating insulin+ cells at embryonic age E18.5
|
• at age P35
|
homeostasis/metabolism
• increased activation of unfolded protein response (UPR) pathway in E18.5 pancreas and cultured isolated islets from P14 pancreas
|
• at age P1 and P14
• at P56
• insulin sensitivity
• dramatically decreased circulating glucose-stimulated insulin levels at age P56
|
• at age P1 and P14
• at P56
|
• severely reduced at age P28, barely detectable at age P56
|
cellular
• increased apoptosis of beta cells at age P14
|
• decreased number of proliferating insulin+ cells at age P1 and P14
• number of proliferating insulin+ cells at embryonic age E18.5
|
• increased activation of unfolded protein response (UPR) pathway in E18.5 pancreas and cultured isolated islets from P14 pancreas
|
growth/size/body
• body weight and size of newborn mice significantly reduced, never attaining wild-type weight or size at age P56
|
• body weight and size of newborn mice significantly reduced, never attaining wild-type weight or size at age P56
|
• body weight of newborn mice significantly lower, never attaining wild-type weight at age P56
|
• embryo weight significantly lower at E18.5
|
adipose tissue
• weight of epididymal fat pads reduced by around 90%
|
behavior/neurological
polydipsia
(
J:211812
)
• significantly increased water consumption at age P56
|